According to this article from the New York Times, only 22 percent of prescription spending is the US is spent on generic drugs, the rest is name brands prescribed by physicians. Major drug companies cut deals with generic manufacturers granting who can market them and I see this as having a pricing...
The Medical Quack .... by Barbara Duck
The Medical Quack
Wed, Jan 13 2010
Filed under: Filed under: Medically Related, Pharma/FDA News, Pharma, Prescriptions, Generic Drugs, Merck, Politics, Patents, Amgen, Teva, FTC, heatlhcare reform, anti-trust, intellctual property, drug deals